** Shares of therapy developer Trevi Therapeutics TRVI.O rise 21.9% to $5.24 premarket
** Co says its therapy, Haduvio, met the main goal in a mid-stage trial testing in patients with a type of chronic cough
** Says therapy showed statistically significant reduction in 24-hour cough frequency
** Currently, there are no approved treatments in the U.S. for coughing bouts that don't have no identifiable cause or those that persist despite treatment of underlying conditions
** GSK GSK.L has a chronic cough treatment in development, and Merck has an experimental drug for the disease which faced two FDA rejections in the past
** Up to last close, TRVI up 45.8% in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。